Methods of treating cardiometabolic diseases

A compound of Formula (III-D):

• or a pharmaceutically acceptable salt, stereoisomer, tautomer, or deuterated form thereof wherein:
• R1 is —C1-6 haloalkyl, halo, or —NR8R9;
• R2 is independently halo, —CN, —C1-6 alkyl, —C1-6 alkylene-carbocyclyl, —C1-6 alkylene-heterocyclyl, or —C1-6 haloalkyl;
• R3 is —H, halo, —C1-6 alkyl, or —C1-6 haloalkyl;
• R4 is halo, —CN, —OH, —O—C1-6alkyl, —C1-6alkyl, —C1-6 alkyl-CN, —C1-6 haloalkyl, —C(O)NR8R9, —C(O)OR8, —NR8R9, —NR8C(O)R9, heterocyclyl, heteroaryl, or carbocyclyl;
• or R3 and R4 are taken together to form heteroaryl, carbocyclyl, or heterocyclyl, each of which may be substituted with one or more halo, —C1-6 haloalkyl, —C1-6alkyl, —CN, —OH, —NH2, —NH(alkyl), or —N(alkyl)2;
• R5A, R5B, R6A, and R6B are each independently —H, halo, or —C1-6 alkyl;
• or
• one of R5A and R5B is joined with one of R6A and R6B to form an optionally substituted C3-8 carbocyclic ring, or an optionally substituted 3-8 membered heterocyclic ring;
• and
• R7 is —H, —C1-6alkyl or halo;
• and
• R8 and R9 are each independently —H, —C1-6 alkyl, aryl or heteroaryl.